MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ajh/hpaa149

Медицинская библиотека · American journal of hypertension · 2020

Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.

Soleimani Abbas, Kazemian Sina, Karbalai Saleh Shahrokh, Aminorroaya Arya, Shajari Zahra, Hadadi Azar, Talebpour Mohammad, Sadeghian Hakimeh, Payandemehr Pooya, Sotoodehnia Mehran, Bahreini Maryam, Najmeddin Farhad, Heidarzadeh Ali, Zivari Ensieh, Ashraf Haleh

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

There is an ongoing controversy about harms and benefits of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in hypertensive patients with coronavirus disease 2019 (COVID-19). Given the unresolved debate, we investigated the association of ARBs with in-hospital outcomes of these patients.

METHODS

In this retrospective observational study, we studied patients with COVID-19 who referred to Sina Hospital in Tehran, Iran, from 20 February to 29 May 2020. Patients with either positive real-time reverse-transcriptase polymerase-chain-reaction test of swab specimens, or high clinical suspicion according to the World Health Organization's interim guidance were included. We followed-up patients for incurring death, severe COVID-19, and in-hospital complications.

RESULTS

We evaluated 681 patients with COVID-19 of whom 37 patients were excluded due to incomplete medical records and 8 patients who used ACEIs which left 636 patients in the analysis. In this cohort, 108 (17.0%) patients expired and 407 (64.0%) patients incurred severe COVID-19. Of 254 (39.9%) patients with hypertension, 122 (48.0%) patients were receiving an ARB. After adjustment for possible confounders, we found no independent association between taking ARBs and in-hospital outcomes except for acute kidney injury (AKI), in patients with confirmed or clinically suspected COVID-19, either hypertensive or not-hypertensive. We found that discontinuation of ARBs during hospitalization was associated with a greater risk of mortality, invasive ventilation, and AKI (all P ˂ 0.002).

CONCLUSIONS

We found that taking ARBs by patients with hypertension and confirmed or clinically suspected COVID-19 is not associated with poorer in-hospital outcomes after adjustment for possible confounders.

Для цитирования: Soleimani Abbas, Kazemian Sina, Karbalai Saleh Shahrokh, Aminorroaya Arya, Shajari Zahra, Hadadi Azar, Talebpour Mohammad, Sadeghian Hakimeh, Payandemehr Pooya, Sotoodehnia Mehran, Bahreini Maryam, Najmeddin Farhad, Heidarzadeh Ali, Zivari Ensieh, Ashraf Haleh. Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.. American journal of hypertension. 2020. DOI: 10.1093/ajh/hpaa149.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.